NEW MANUFACTURING CHANGE REGULATIONS
This article was originally published in The Gold Sheet
Executive Summary
...and supporting guidance are emerging from FDA under pressure to meet tight FDAMA timelines. A final guidance detailing the agency’s interpretation of the new regulations is expected to be completed in 1999, with the final 314.70 rule to follow next year. The agency does not intend to overhaul the companion guidance in spite of a perceived lack of regulatory relief in the proposed draft, although some adjustments are being made relating, for example, to compendial revisions and sterile products. FDA and industry are gaining experience with comparability protocols as a mechanism for expediting manufacturing changes. [A discussion by a center for biologics official of successful comparability protocol filings is included beginning on p. 11.]
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.